Clinicopathologic significance of histologic grade, Pgp, and p53 expression in canine lymphoma

Journal of the American Animal Hospital Association

Volumn 49, Issue 3, 2013, Pages 175-184

  Dhaliwal, Ravinder S ^d   Kitchell, Barbara E ^a   Ehrhart, E J ^b   Valli, Victor E ^c   Dervisis, Nikolaos G ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c VDX VETERINARY DIAGNOSTICS   (United States)

^d VCA All Care Animal Referral Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53; TUMOR MARKER;

ANIMAL; ANIMAL DISEASE; ARTICLE; CANCER GRADING; DOG; DOG DISEASE; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; NONHODGKIN LYMPHOMA; PATHOLOGY; REMISSION; SURVIVAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOG DISEASES; DOGS; FEMALE; IMMUNOHISTOCHEMISTRY; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASM GRADING; P-GLYCOPROTEIN; REMISSION INDUCTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

MLCS; MLOWN;

EID: 84879566223     PISSN: 05872871     EISSN: 15473317     Source Type: Journal    
DOI: 10.5326/JAAHA-MS-5843     Document Type: Article

References (51)

1. Moulton JE, Harvey JW. Tumors of lymphoid and hematopoietic tissue. In: Moulton JE, ed. Tumors of domestic animals. 3rd ed. Berkeley (CA): University of California Press; 1990:231-307.
2. Dorn CR, Taylor DON, Frye FL, et al. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. I. Methodology and description of cases. J Natl Cancer Inst 1968;40(2):295-305.
3. Northrup NC, Gieger TL, Kosarek CE, et al. Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs. Vet Comp Oncol 2009;7(1):38-44.
4. Bannink EO, Sauerbrey ML, Mullins MN, et al. Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999-2006). J Am Vet Med Assoc 2008;233(3):446-51.
5. Brenn SH, Couto SS, Craft DM, et al. Evaluation of P-glycoprotein expression in feline lymphoma and correlation with clinical outcome. Vet Comp Oncol 2008;6(3):201-11.
6. Uozurmi K, Nakaichi M, Yamamoto Y, et al. Development of multidrug resistance in a canine lymphoma cell line. Res Vet Sci 2005;78(3):217-24.
7. Fojo AT, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005;32(6)(suppl 7): S3-8.
8. Murren JR. Modulating multidrug resistance: can we target this therapy? [editorial]. Clin Cancer Res 2002;8(3):633-5.
9. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989;58:137-71.
10. Marie JP. P-glycoprotein in adult hematologic malignancies. Hematol Oncol Clin North Am 1995;9(2):239-49.
11. Moore AS, Leveille CR, Reimann KA, et al. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Invest 1995;13(5):475-9.
12. Bergman PJ, Ogilvie GK, Powers BE. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma. J Vet Intern Med 1996;10(6):354-9.
13. Lee JJ, Hughes CS, Fine RL, et al. P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 1996;77(9):1892-8.
14. Miyoshi N, Tojo E, Oishi A, et al. Immunohistochemical detection of P-glycoprotein (PGP) and multidrug resistance-associated protein (MRP) in canine cutaneous mast cell tumors. J Vet Med Sci 2002;64(6):531-3.
15. Guo A, Marinaro W, Hu P, et al. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos 2002;30(4):457-63.
16. Sueiro FA, Alessi AC, Vassallo J. Canine lymphomas: a morphological and immunohistochemical study of 55 cases, with observations on p53 immunoexpression. J Comp Pathol 2004;131(2-3): 207-13.
17. Veldhoen N, Stewart J, Brown R, et al. Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog. Oncogene 1998;16(2):249-55.
18. Gamblin RM, Sagartz JE, Couto CG. Overexpression of p53 tumor suppressor protein in spontaneously arising neoplasms of dogs. Am J Vet Res 1997;58(8):857-63.
19. Ginn PE. Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues. Vet Pathol 1996;33(5):533-41.
20. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351(6326):453-6.
21. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70(4):523-6.
22. Sagartz JE, Bodley WL, Gamblin RM, et al. p53 tumor suppressor protein overexpression in osteogenic tumors of dogs. Vet Pathol 1996;33(2):213-21.
23. Soko1owska J, Cywinska A, Malicka E. p53 expression in canine lymphoma. J Vet Med A Physiol Pathol Clin Med 2005;52(4):172-5.
24. Setoguchi A, Sakai T, Okuda M, et al. Aberrations of the p53 tumor suppressor gene in various tumors in dogs. Am J Vet Res 2001;62(3): 433-9.
25. Lee CH, Kim WH, Lim JH, et al. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. J Vet Sci 2004;5(1):63-9.
26. Lee CH, Kweon OK. Mutations of p53 tumor suppressor gene in spontaneous canine mammary tumors. J Vet Sci 2002;3(4):321-5.
27. Lowe SW, Ruley HE, Jacks T, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74(6): 957-67.
28. Finlay CA, Hinds PW, Tan TH, et al. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8(2): 531-9.
29. Axiotis CA, Monteagudo C, Merino MJ, et al. Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma. Am J Pathol 1991;138(4):799-806.
30. Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998;58(6):1149-58.
31. Boyce KL, Kitchell BE. Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000;36(5):395-403.
32. Greenlee PG, Filippa DA, Quimby FW, et al. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 1990; 66(3):480-90.
33. Teske E, van Heerde P, Rutteman GR, et al. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1994;205(12):1722-8.
34. Valli VE, San Myint M, Barthel A, et al. Classification of canine malignant lymphomas according to the World Health Organization criteria. Vet Pathol 2011;48(1):198-211.
35. Dhaliwal RS, Kitchell BE, Messick J. Canine Lymphosarcoma. Comp Cont Educ Pract Vet 2003;25:572-82.
36. Arao S, Suwa H, Mandai M, et al. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 1994;54(5):1355-9.
37. Pileri SA, Sabattini E, Falini B, et al. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 1991; 19(2):131-40.
38. Miller TP, Grogan TM, Dalton WS, et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 9(1):17-24.
39. Bell DR, Gerlach JH, Kartner N, et al. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol 1985;3(3):311-5.
40. Stewart J, Gorman NT. Multi-drug resistance genes in the management of neoplastic disease. J Vet Intern Med 1991;5(4):239-47.
41. Dalton WS. Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 1997;11(5):975-86.
42. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258(5088):1650-4.
43. Filipits M, Suchomel RW, Zöchbauer S, et al. Multidrug resistanceassociated protein in acute myeloid leukemia: No impact on treatment outcome. Clin Cancer Res 1997;3(8):1419-25.
44. Bosari S, Viale G, Roncalli M, et al. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 1995;147(3):790-8.
45. Baas IO, Mulder JW, Offerhaus GJ, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172(1): 5-12.
46. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54(18):4855-78.
47. Pezzella E, Morrison H, Jones M, et al. Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology 1995;22(1):39-44.
48. Said JW, Barrera R, Shintaku IP, et al. Immunohistochemical analysis of p53 expression in malignant lymphomas. Am J Pathol 1992;141(6):1343-8.
49. Wunder JS, Gokgoz N, Parkes R, et al. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 2005; 23(7):1483-90.
50. Zhang C, Zhang P, Hao J, et al. High nuclear grade, frequent mitotic activity, cyclin D1 and p53 overexpression are associated with stromal invasion in mammary intracystic papillary carcinoma. Breast J 2005;11(1):2-8.
51. Jones BA, Kasl SV, Howe CL, et al. African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 2004;101(6):1293-301.